Quick Answer
Bergamot Cholesterol Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool.
Key Takeaways
- 01Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool. [Pujia C (2026)]
- 02This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the effect of nutraceuticals containing Citrus bergamia on the management of obesity in adults by assessing measures related to obesity. [Pujia C (2026)]
- 03We searched the following databases until October 2024: PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials. [Pujia C (2026)]
- 041 2 3 2 3 4 5 6 Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, primarily driven by a combination of non-modifiable (gender and family history) and modifiable (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity) risk factors. [Carpenito Myriam (2025)]
The current Migaku evidence database contains 2 reusable source documents for Bergamot Cholesterol Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool. [Pujia C (2026); evidence level 1]
- This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the effect of nutraceuticals containing Citrus bergamia on the management of obesity in adults by assessing measures related to obesity. [Pujia C (2026); evidence level 1]
- We searched the following databases until October 2024: PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials. [Pujia C (2026); evidence level 1]
- 1 2 3 2 3 4 5 6 Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, primarily driven by a combination of non-modifiable (gender and family history) and modifiable (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity) risk factors. [Carpenito Myriam (2025); evidence level 3]
- Among modifiable risk factors, low-density lipoprotein cholesterol (LDL-C) is recognized as the most significant contributor to atherosclerosis [,,]. [Carpenito Myriam (2025); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources